256 related articles for article (PubMed ID: 16336855)
1. [Somatostatin receptor scintigraphy].
Rasmussen K; Nielsen JT; Rehling M
Ugeskr Laeger; 2005 Dec; 167(49):4647-50. PubMed ID: 16336855
[TBL] [Abstract][Full Text] [Related]
2. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
[TBL] [Abstract][Full Text] [Related]
5. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
[No Abstract] [Full Text] [Related]
6. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors.
Meko JB; Doherty GM; Siegel BA; Norton JA
Surgery; 1996 Dec; 120(6):975-83; discussion 983-4. PubMed ID: 8957483
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
9. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
Balon HR; Goldsmith SJ; Siegel BA; Silberstein EB; Krenning EP; Lang O; Donohoe KJ;
J Nucl Med; 2001 Jul; 42(7):1134-8. PubMed ID: 11438641
[No Abstract] [Full Text] [Related]
10. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
Savelli G; Lucignani G; Seregni E; Marchianò A; Serafini G; Aliberti G; Villano C; Maccauro M; Bombardieri E
Nucl Med Commun; 2004 May; 25(5):445-9. PubMed ID: 15100502
[TBL] [Abstract][Full Text] [Related]
12. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.
Asnacios A; Courbon F; Rochaix P; Bauvin E; Cances-Lauwers V; Susini C; Schulz S; Boneu A; Guimbaud R; Buscail L
J Clin Oncol; 2008 Feb; 26(6):963-70. PubMed ID: 18281671
[TBL] [Abstract][Full Text] [Related]
13. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
Garin E; Le Jeune F; Devillers A; Cuggia M; de Lajarte-Thirouard AS; Bouriel C; Boucher E; Raoul JL
J Nucl Med; 2009 Jun; 50(6):858-64. PubMed ID: 19443590
[TBL] [Abstract][Full Text] [Related]
16. [A new diagnostic method: somatostatin receptor scintigraphy of neuroendocrine tumors].
Westlin JE; Janson ET; Ahlström H; Ohrvall U; Arnberg H; Nilsson S; Akerström G; Oberg K
Lakartidningen; 1992 Dec; 89(50):4377-9. PubMed ID: 1469974
[No Abstract] [Full Text] [Related]
17. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
19. Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy.
Weinel RJ; Neuhaus C; Stapp J; Klotter HJ; Trautmann ME; Joseph K; Arnold R; Rothmund M
Ann Surg; 1993 Nov; 218(5):640-5. PubMed ID: 7902072
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
